Science Translational Medicine Review Time

AAAS describes Science Translational Medicine very clearly as a weekly translational journal at the intersection of science, engineering, and medicine. The official materials explain scope and readership well.

They tell you:

• the journal is genuinely translational in identity

• interdisciplinary bench-to-bedside work is the intended lane

• the readership spans basic, applied, and translational scientists

They do not tell you:

• a public median time to first decision

• a public median time to acceptance

• how long borderline manuscripts spend in editorial discussion before send-out

That means the timing model here has to come from:

• official scope language, which explains why the fit screen is so aggressive

• current author-reported handling data, which show the sharp difference between desk rejects and accepted papers

STM is therefore a journal where editorial selection pressure creates the timing curve.

That is why STM can feel brutally fast and frustratingly slow at the same time.

The journal's triage logic is fairly unforgiving. Papers tend to get rejected quickly when they are:

• elegant basic science with translational language added late

• animal-only packages with weak human relevance

• mechanistically strong but too early for a translational journal

• clinically interesting without enough mechanistic explanation

• better suited to Nature Medicine, JCI, Science Advances, or a field-specific journal

The fast desk behavior is not random. It reflects a journal that knows the translational bridge has to be the story, not the marketing line.

The slower cases are usually the ones that survive the first translational smell test and then get challenged on whether the bridge is actually durable.

The common causes are:

• reviewer disagreement over how real the human relevance is

• demands for stronger mechanistic support under the translational claim

• multiple revision rounds testing clinical feasibility or biological grounding

• manuscripts that look exciting but still have one weak link in the bench-to-bedside chain

• accepted papers needing editorial refinement beyond standard reviewer comments

When STM feels slow, it is often because the manuscript is being forced to prove that the translational step is real, not decorative.

For year-over-year citation metrics data, see the science translational medicine citation metric page.

Science Translational Medicine fell from 15.8 in 2023 to 14.6 in 2024, then moved back to a 15.6 2025 JIF in the 2026 JCR release.

For review time, the useful implication is that the journal still has enough status to keep a very hard desk filter. It does not need to soften the translational standard to stay visible.

The public-facing and author-reported data still hide several important things:

• fast desk rejection does not mean fast peer review for surviving files

• multiple rounds are common in the accepted-paper path

• the translational weak link is often what drives delay, not reviewer laziness

• timing cannot repair a manuscript whose bridge to application is mostly aspirational

So the clock is real, but the bridge quality is more important.

In our pre-submission review work, the biggest timing mistake is assuming that any paper with disease relevance and strong biology should first test STM because the rejection will come quickly if it is wrong.

That is only partly true.

The papers that move best here usually have:

• a translational hypothesis built into the design rather than into the discussion

• some form of human or human-relevant evidence supporting the bridge

• a mechanistic claim strong enough that clinically minded reviewers can trust the biology

• a title and abstract that already read like translational medicine, not basic science dressed up

Those traits make the desk filter less dangerous and the longer review path more rational.

For Science Translational Medicine-targeted manuscripts, three patterns most consistently predict slow review at Science Translational Medicine (AAAS). Of manuscripts we screened in 2025 targeting Science Translational Medicine and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: Science Translational Medicine professional editors emphasize translational-research framework with both mechanistic depth and clinical-application pathway.

Scope-fit ambiguity in the abstract. Science Translational Medicine editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (translational research). The named failure pattern: mechanism-only papers without clinical-translation pathway extend revision rounds. Check whether your abstract reads to Science Translational Medicine's scope →

Methods package incomplete for the journal's reviewer pool. Science Translational Medicine reviewers expect specific methodological detail. Clinical observational studies without mechanistic underpinning extend reviewer consultation. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. Editorial team at Science Translational Medicine (AAAS) screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: AAAS journal page. Manuscript constraints: 125-word abstract limit and 5,500-word main-text cap (Science Translational Medicine enforces during desk-screen).

We reviewed each of these constraints against current journal author guidelines (accessed 2026-05-08); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights submission-corpus signal for Science Translational Medicine (AAAS). Of the manuscripts our team screened before submission to Science Translational Medicine and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is Science Translational Medicine professional editors emphasize translational-research framework with both mechanistic depth and clinical-application pathway.

In our analysis of anonymized Science Translational Medicine-targeted submissions, the documented review timeline shows a bimodal distribution between manuscripts that clear Science Translational Medicine's scope-fit threshold within the first week and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.

For STM, timing matters less than translational architecture. The better question is whether the manuscript already behaves like a bench-to-bedside paper.

That is why the better next reads are:

• Science Translational Medicine journal profile

• Science Translational Medicine submission guide

• Science Translational Medicine citation metric

• How to choose the right journal

A Science Translational Medicine fit check is usually more valuable than fixating on the first-decision speed.

Science Translational Medicine review time is fast for clear noes and materially longer for serious candidates. That split is the point, not a flaw. If the translational bridge is real, the longer process can make sense. If the paper only sounds translational after rhetorical framing, STM usually reveals that quickly.

The Manusights Science Translational Medicine readiness scan. This guide tells you what Science Translational Medicine (AAAS)'s editors look for in the first 1-2 weeks of triage. The review tells you whether your paper passes that check before you submit.

We have reviewed manuscripts targeting Science Translational Medicine (AAAS) and peer venues; the named patterns below are the same ones the journal's handling editors and outside reviewers flag at the desk-screen and first-review stages. documented review timeline of approximately 7-10 days for desk-screen. 60-day money-back guarantee. Your manuscript is not used for model training, and access is limited to the review workflow.

Past the desk screen and into review? The Science Translational Medicine Under Review status guide shows what to watch for and what to prepare while you wait.